Efficacy of Tenapanor in Managing Hyperphosphatemia and Constipation in Hemodialysis Patients: A Randomized Controlled Trial

Efficacy of Tenapanor in Managing Hyperphosphatemia and Constipation in Hemodialysis Patients: A Randomized Controlled Trial - Tenapanor for Hyperphosphatemia and Constipation Study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000056561

Enrollment

100

Registered

2024-12-25

Start date

2024-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease

Interventions

Intervention: Patients who started taking tenaponar. Treatment for 23 weeks. The starting dose was 10 mg/day, and the dose was adjusted by each treating physician according to the serum phosphorus lev

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adult patients on maintenance dialysis who received dialysis treatment at the clinic affiliated with Momonikai Hospital between February 1, 2024 and February 31, 2024.

Exclusion criteria

Exclusion criteria: Exclusion criteria were as follows; (1) patients had to have been undergoing hemodialysis for at least 2 years at baseline, (2) Patients with a history of or current inflammatory bowel disease or diarrhea-type irritable bowel syndrome, and (3) CRP was 1.0 mg/dL or higher.

Design outcomes

Primary

Measure	Time frame
Changes in serum phosphorus levels, changes in stool characteristics (Bristol Stool Characteristics Score), and changes in laxative prescription during the observation period.	—

Countries

Japan

Contacts

Public ContactNaoki Suzuki

Tojinkai Hospital Data Science Department

suzuki@tojinkai.jp0756221991

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026